Overview

Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and clinical efficacy of the combination of panobinostat plus bortezomib.
Phase:
Phase 1
Details
Lead Sponsor:
Anand Jillella
Collaborator:
Novartis Pharmaceuticals
Treatments:
Bortezomib
Panobinostat